TNFRSF9 and neoplasm: While wild-type IL-2 has a very short half-life precluding significant tumor accumulation following a single systemic administration34, extended-PK IL-2-Fc circulates long enough to accumulate in tumors, together with the long half-life anti-CD137 antibody.